Oropouche virus (OROV) is a neglected vectorborne orthobunyavirus that has caused Oropouche fever in the Amazon region since the 1950s (1,2). OROV infection usually causes febrile illness but can also lead to neurologic diseases, pregnancy complications, and death (1,3–7). OROV is primarily transmitted to humans by Culicoides paraenesis midges in the human-amplified and enzootic cycles, and palethroated sloths are potential amplifier hosts (1,8). As of March 2025, no specific antiviral drugs or vaccines were available to treat or prevent Oropouche fever. Oropouche fever burden remains undetermined, but some studies have estimated >500,000 cases in the Amazon Basin since the 1950s (1). In November 2023, a substantial increase in the incidence of Oropouche fever was observed in the Amazon region in Brazil, Bolivia, Peru, and Colombia (4,9). The reemergence has been linked with the novel OROV reassortant identified in the Amazon Basin and later spread to previously nonendemic areas (9–11). However, knowledge about introducing and establishing OROV outside the Amazon region remains limited. We conducted a molecular epidemiology study to investigate the active circulation of OROV in patients with acute febrile illness in 2024 in Ceará state, Brazil.